Galapagos NV (NASDAQ:GLPG) is one of the
7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to Ouro’s clinical-stage asset gamgertamig, a BCMAxCD3 T cell engager, along with additional preclinical programs. Under the agreement, Galapagos will obtain licenses to key intellectual property, assume certain development responsibilities, and gain operational assets including facilities and personnel, effectively establishing an operating business tied to the programs. The framework also allows Galapagos to deploy at least $500M of its cash independently, including up to $150M for potential share buybacks.
Gamgertamig has received Fast Track and Orphan Drug Designation from the FDA for AIHA and ITP and is expected to enter registrational studies as early as 2027. Galapagos will fund early-stage development, while later-stage costs will be shared with Gilead, which will lead global commercialization outside certain territories. The company is also eligible for milestone payments and tiered royalties ranging from 20% to 23% on net sales.
Copyright: zneb076 / 123RF Stock Photo
On March 26, 2026, Galapagos NV (NASDAQ:GLPG) also announced the proposed appointment of Gino Santini as a non-executive independent director and future chair of the board, subject to shareholder approval at its April 28 annual meeting.
Galapagos NV (NASDAQ:GLPG) develops therapies focused on oncology and immunology.
While we acknowledge the potential of GLPG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.